Skip to main content

Inpatient diabetes

08-22-2022 | COVID-19 | News

Glucokinase activator may improve severe COVID-19 outcomes in people with diabetes

Findings from the phase 2 ARCADIA trial suggest that treatment with a glucokinase activator may aid the recovery of people with diabetes who are hospitalized with severe COVID-19.

11-04-2021 | Older adults | News | Article

Hospital discharge not best time to intensify diabetes medication in older adults

Intensification of diabetes medications in older adults at the point of discharge from hospital is associated with an increased risk for hypoglycemia, without gains in glycemic control, research suggests.

03-25-2021 | Ketoacidosis | News

Mortality twice as likely with early DKA readmission

Readmission to hospital within a month of admission for diabetic ketoacidosis is common and associated with an increased mortality risk, say researchers.

02-18-2021 | COVID-19 | News

Metformin among factors linked to favorable COVID-19 outcomes

The latest report from the CORONADO study reveals factors predictive of home discharge within 28 days among people with diabetes hospitalized with COVID-19, as well as those linked to mortality risk.

02-15-2021 | COVID-19 | News

Glycemic fluctuations linked to poor COVID-19 outcomes

Elevated glucose levels and glycemic fluctuations during the first week of hospitalization for COVID-19 are associated with an increased risk for unfavorable outcomes, research suggests.

02-08-2021 | COVID-19 | News

No need to discontinue DPP-4 inhibitors during hospitalization for COVID-19

Results from the CORONADO study indicate that use of DPP-4 inhibitors does not affect outcomes for people with type 2 diabetes admitted to hospital with COVID-19.

01-04-2021 | COVID-19 | News

COVID-19 risk not equal among people with diabetes

The risk for fatal or critical care unit-treated COVID-19 varies among people with diabetes and can be reasonably well predicted by their clinical history, UK study findings indicate.

10-30-2020 | COVID-19 | News

Diabetes does not impair COVID-19 antibody response

The humoral immune response to SARS-CoV-2 infection is similar in people with and without diabetes and is not influenced by hyperglycemia, research suggests.